Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting

FLEX Study Highlights Clinical Utility of MammaPrintยฎ and BluePrintยฎ Read More

2025-05-22T21:59:22-04:00May 27th, 2025|Press Releases|

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024

Gene expression analysis reveals MammaPrintยฎ as the only commercially Read More

2025-04-17T13:43:12-04:00December 12th, 2024|Press Releases|

Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024

New data reinforces findings from MINDACT supporting MammaPrintยฎ in Read More

2025-04-17T13:43:47-04:00December 11th, 2024|Press Releases|

Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit

A secondary analysis of the randomized controlled trial, IDEAL, Read More

2025-04-17T13:44:21-04:00December 2nd, 2024|Press Releases|

Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024

New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ€™ expanding clinical Read More

2025-04-17T13:46:07-04:00November 25th, 2024|Press Releases|
Go to Top